Luigi Lorini: Coming back from ESMO 2024 with many thoughts in my mind

Luigi Lorini shared on LinkedIn:

“Coming back from ESMO 2024 with many thoughts in my mind:

– I’m pleased to have presented the poster regarding the safety of the neoadjuvant phase of the prime trial: a phase 2 single arm center of perioperative treatment for LAHNSCC with PARPi (niraparib) and PD1/PDL1i (dostarlimab) —> treatment is safe, no unexpected toxicities, only 1 patients delayed of 2 week planned surgery. Let’s await for activity data (primary endpoint is mayor pathological response) and translational data!

Thanks to dr Erika Stucchi for the great contribution on such work

– congrats to Irene Brana for the great HN highlights session;

– thanks to all my team Paolo Bossi, Carlo Resteghini, Cristina Gurizzan, Davide Smussi for the paper presented, the oral talks, and the ideas shared during these intensive days;

– It was gratifying to reconnect with old friends and establish new connections for future research projects;

– HN cancer still represents an unmet medical need in the oncological fields, both in terms of active treatment and quality of life! I’m thrilled to move forward with project on going and designing new trials!”

Source: Luigi Lorini/LinkedIn

Best of ESMO24

Luigi Lorini is a Medical Oncologist at Humanitas Research Hospital. He previously served as a Resident Doctor in the Medical Oncology Unit at the University of Brescia and completed a Research Fellowship in Medical Oncology at the Head and Neck Unit of Vall d’Hebron Barcelona Hospital Campus.